Atrandi Biosciences Partners with KAIST, Supported by Lithuania's Ambassador to South Korea
We are thrilled to announce the successful installation of South Korea’s first STYX high-throughput screening system at the Korea Advanced Institute of Science and Technology (KAIST). This milestone marks an exciting step in our mission to empower cutting-edge research worldwide, advancing single-cell analysis and ultra-high-throughput screening capabilities.
The installation at KAIST represents a key milestone in our strategic expansion into the Asia-Pacific region, reinforcing our commitment to enabling transformative scientific discoveries through innovative technology.
Atrandi Biosciences, KAIST and Lithuania's ambassador to South Korea midst installation of STYX
Pioneering Research at KAIST with STYX
Professor Sungmin Son, leading the charge in KAIST’s Bio and Brain Engineering department, is utilizing the STYX platform to drive novel advancements in molecular and cellular property analysis at the individual level.
“STYX offers a seamless turn-key sorting solution while also allowing the flexibility to develop and integrate new functionalities. Its versatility makes STYX an invaluable asset for the protein engineering and the novel single-cell screening projects I have planned for my lab,” said Professor Son.
The adoption of the STYX system by KAIST is expected to propel the institution to the forefront of life sciences research, catalyzing breakthroughs in protein engineering, drug discovery, and single-cell biology.
Since our founding in 2016, Atrandi Biosciences has been committed to advancing the frontiers of biotechnology through innovative microfluidic platforms. With over 100 installations globally, spanning Europe and North America, our entry into South Korea underscores the growing importance of the region in the global life sciences ecosystem.
“South Korea is rapidly establishing itself as a leading force in the global life sciences industry, distinguished by its exceptional growth and innovation. The country’s highly skilled talent pool, coupled with a robust network of research institutes, universities, and private companies, makes it one of the most significant and fastest-evolving markets in biotechnology. We are thrilled to support top-notch science in the region,” said Juozas Nainys, PhD, CEO of Atrandi Biosciences.
Strengthening Global Partnerships
This collaboration between Atrandi Biosciences and KAIST also highlights the strengthening ties between Lithuania and South Korea in the biotechnology sector. The forthcoming establishment of a South Korean embassy in Lithuania underscores the growing significance of these collaborations.
As Ambassador Ricardas Slepavicius of Lithuania to South Korea aptly noted, “This is one of the examples of our strong commitment to working together in the biotech field, using our shared knowledge and skills to solve global problems and make new advancements in healthcare. I believe it will be a great example for future projects between Lithuania and South Korea, leading to even more successful collaborations.”
Looking Ahead
We are excited to see how the adoption of our STYX platform at KAIST will lead to groundbreaking discoveries and further strengthen Atrandi Biosciences' presence in Asia-Pacific.
Stay tuned for updates on this collaboration and more by following us on LinkedIn or visiting our website.
